Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses

  • L Juurinen
  • , A Kotronen
  • , M Granér
  • , H Yki-Järvinen

    Research output: Contribution to journalArticleScientificpeer-review

    48 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)118-124
    JournalJournal of Clinical Endocrinology And Metabolism
    Volume93
    Issue number1
    Publication statusPublished - 2008
    Publication typeA1 Journal article-refereed

    Cite this